The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | ReKInDLE: a Phase II trial of iberdomide, carfilzomib, daratumumab, & dexamethasone for R/R myeloma
Benjamin Diamond, Dr, Sylvester Comprehensive Cancer Center, Miami, FL, discusses the ReKInDLE trial (NCT05896228), a Phase II study evaluating the iberdomide, carfilzomib, daratumumab, and dexamethasone (IberKDd) quadruplet regimen for relapsed/refractory (R/R) multiple myeloma (MM). Patients enrolled in the study received eight cycles of IberKDd and were then de-escalated to iberdomide monotherapy. Dr Diamond highlights that the regimen was well-tolerated and that the efficacy data are highly encouraging in this heavily pretreated, lenalidomide-refractory patient population. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
